User profiles for "author:Kelley Coffman"
 | Kelley CoffmanNational Cancer Institute Verified email at nih.gov Cited by 50 |
[HTML][HTML] Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
C Monge, C Xie, Y Myojin, K Coffman… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Oncolytic immunotherapy represents a unique therapeutic platform for the
treatment of cancer. Here, we evaluated the safety and efficacy of the combination of …
treatment of cancer. Here, we evaluated the safety and efficacy of the combination of …
Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to lutetium-177-DOTATATE
Introduction: Lutetium-177 (177 Lu)-DOTATATE received FDA approval in 2018 to treat
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs). Little …
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs). Little …
[HTML][HTML] IVIG–A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including …
K Coffman, XJC Chen, C Okamura, E Louie - IDCases, 2017 - Elsevier
The mainstay treatment of Clostridium difficile infections (CDI) is antimicrobials with growing
support for fecal microbiota transplants. We report the first case of an elderly man with …
support for fecal microbiota transplants. We report the first case of an elderly man with …
The current landscape of therapies for hepatocellular carcinoma
K Coffman-D'Annibale, C Xie, DM Hrones… - …, 2023 - academic.oup.com
Globally, primary liver cancer is the third leading cause of cancer-related deaths, with
approximately 830 000 deaths worldwide in 2020, accounting for 8.3% of total deaths from …
approximately 830 000 deaths worldwide in 2020, accounting for 8.3% of total deaths from …
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract …
C Monge, C Xie, Y Myojin… - Cancer …, 2024 - Wiley Online Library
Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine,
cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study …
cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study …
[HTML][HTML] 585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single …
K Coffman, Y Myojin, C Monge, C Xie, DM Hrones… - 2023 - jitc.bmj.com
Background Microsatellite stable colorectal liver metastases (MSS CLM) maintain an
immunosuppressive tumor microenvironment (TME). Historically, immune-based …
immunosuppressive tumor microenvironment (TME). Historically, immune-based …
Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE.
KL Coffman, L Bodei, T Le, Y Choi, JF Chou, M Capanu… - 2021 - ascopubs.org
368 Background: 177Lu-DOTATATE is an approved therapy for somatostatin receptor (sstr)
positive gastroenteropancreatic neuroendocrine tumors (NETs). There are little data …
positive gastroenteropancreatic neuroendocrine tumors (NETs). There are little data …
[HTML][HTML] VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm …
K Coffman-D'Annibale, Y Myojin, C Monge… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Microsatellite stable colorectal liver metastases (MSS CLM) maintain an
immunosuppressive tumor microenvironment (TME). Historically, immune-based …
immunosuppressive tumor microenvironment (TME). Historically, immune-based …
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
C Xie, MC Monge B, D Mabry-Hrones, KL Coffman… - 2023 - ascopubs.org
TPS624 Background: The mortality of hepatocellular carcinoma (HCC) is increasing
worldwide, but outcome of systemic treatments in advanced HCC is suboptimal. Adoptive T …
worldwide, but outcome of systemic treatments in advanced HCC is suboptimal. Adoptive T …
Top advances of the year: Hepatobiliary cancers.
KL Coffman-D'Annibale, TF Greten - Cancer, 2023 - europepmc.org
This commentary reviews top advances in hepatobiliary cancer research in 2021-2022,
focusing on leveraging immunotherapeutics in combination with other therapies earlier in …
focusing on leveraging immunotherapeutics in combination with other therapies earlier in …